top | item 38776867

(no title)

JakeAl | 2 years ago

[flagged]

discuss

It’s been tested for decades. The issue is protein-based platforms deliver the protein outside the cell. This means most do not get processed and presented by MHC-1 and 2 the way a genetically encoded therapeutic does. The issue with DNA is it separates the innate immune activation signal (eg cGAS and TLRs) from the presentation so you don’t get co-signaling. This may be the ticket why mRNA could work…

lame-robot-hoax|2 years ago

Why is that the question to ask?

SV_BubbleTime|2 years ago

Maybe we found out in 20 years there is an mRNA to DNA long term issue? Maybe it’s good to not just one-path cancer treatments?